Can-fite BioPharma – About the Company
Can-Fite BioPharma (NYSE MKT: CANF) is a clinical stage biopharmaceutical company developing therapeutics for cancer, inflammatory diseases, and sexual dysfunction. The Company’s product candidates are based on a validated and proprietary technology platform that involves the A3 adenosine G protein-coupled receptor (A3AR), which is highly expressed on inflammatory and cancer cells. Can-Fite’s lead product candidate CF101, an A3AR agonist for the treatment of rheumatoid arthritis (RA) and psoriasis, has demonstrated efficacy in Phase II clinical trials and is poised to enter Phase III trials in the second half of 2016. Can-Fite’s product candidate for liver cancer and NASH is CF102, a second-generation A3AR agonist that reduces inflammation and inhibits tumor cell growth. The Company is currently conducting a Phase II trial for CF102 in patients with hepatocellular carcinoma and plans to initiate a Phase II study in NASH by the end of the year. Can-Fite also plans to initiate a Phase I study with its allosteric A3AR regulator CF602 in erectile dysfunction by the end of 2016.